The Future of GDNF in Parkinson's Disease

Authors

Fredric P. Manfredsson, Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, United States.Follow
Nicole K. Polinski, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, United States.
Thyagarajan Subramanian, Department of Neurology and Neural and Behavioral Sciences, Penn State University College of Medicine, Hershey, PA, United States.
Nicholas Boulis, Department of Neurosurgery, Emory University, Atlanta, GA, United States.
Dustin R. Wakeman, Virscio, Inc., New Haven, CT, United States.
Ronald J. Mandel, Department of Neuroscience, University of Florida, Gainesville, FL, United States.

Document Type

Article

Keywords

GDNF (glial cell line-derived neurotrophic factor), Parkinson's disease, clinical trial (2.172), gene therapy (GT), neurotrophic factor, neurturin

Publication Date

1-1-2020

Publication Title

Frontiers in aging neuroscience

ISSN

1663-4365

Volume

12

First Page

593572

PubMed ID

33364933

Digital Object Identifier (DOI)

10.3389/fnagi.2020.593572

Recommended Citation

Manfredsson, Fredric P.; Polinski, Nicole K.; Subramanian, Thyagarajan; Boulis, Nicholas; Wakeman, Dustin R.; and Mandel, Ronald J., "The Future of GDNF in Parkinson's Disease" (2020). Translational Neuroscience. 1461.
https://scholar.barrowneuro.org/neurobiology/1461